Understanding Side Effect Differences Between These Treatments
Wegovy vs Mounjaro Side Effects: Mechanism-Based Differences
The side effect profiles of Wegovy and Mounjaro stem from their distinct mechanisms of action. Wegovy (semaglutide) exclusively targets GLP-1 receptors, creating a specific pattern of gastrointestinal effects that typically include nausea, vomiting, and diarrhoea. Clinical data shows these effects occur in approximately 44%, 24%, and 30% of Wegovy patients respectively during the STEP trials. Mounjaro (tirzepatide) acts on both GIP and GLP-1 receptors, which may contribute to different side effect frequencies and intensities. The dual mechanism can result in varying tolerability profiles, with some patients experiencing different gastrointestinal patterns compared to single-receptor treatments.
Understanding these mechanism-based differences helps explain why some individuals may tolerate one treatment better than the other. The GIP receptor activation in Mounjaro may influence how the medication affects gastric emptying and insulin sensitivity, potentially creating a distinct side effect experience. Both treatments are prescription-only medicines requiring careful clinical assessment to determine suitability. At EverydayMeds, our prescribers evaluate your medical history alongside these mechanism differences to recommend the most appropriate option for your individual circumstances.
Wegovy vs Mounjaro Side Effects: Complete Pricing Comparison
When comparing Wegovy vs Mounjaro side effects and costs, EverydayMeds offers transparent pricing for both treatments. Wegovy single pens range from £79.99 (0.25mg starter dose) to £209.99 (2.4mg maintenance dose), with our Progress Duo bundle (0.5mg & 1mg) available for £189.99. New customers receive code FIRST40 applied at checkout, whilst returning customers use code DOSE25. Our bundle options provide convenient multi-month supplies, such as the Ultimate Stability Trio offering three months of 2.4mg maintenance pens for £649.99. This pricing structure allows you to budget effectively whilst managing any side effects through gradual dose escalation.
The financial aspect of managing side effects becomes important when considering treatment duration and dose adjustments. Some patients may need to remain on lower doses longer if experiencing significant side effects, affecting their overall treatment cost. Our flexible pricing accommodates various dose progression speeds, whether you require additional 0.25mg pens for extended tolerability phases or progress quickly to maintenance doses. Both Wegovy and Mounjaro are available through our streamlined ordering system, ensuring consistent supply regardless of which treatment your prescriber recommends based on your side effect tolerance expectations.
Clinical Evidence: Wegovy vs Mounjaro Side Effects in Trials
Clinical trial data provides valuable insights into Wegovy vs Mounjaro side effects profiles. In the STEP trials, Wegovy demonstrated specific side effect patterns, with the Wilding et al., NEJM, 2021 study showing that most gastrointestinal effects were mild to moderate and decreased over time. Patients taking Wegovy alongside diet and exercise typically experienced peak side effects during dose escalation periods. The trial data suggests that systematic dose increases help minimise severe side effects whilst maintaining therapeutic effectiveness.
Comparative analysis of trial populations reveals important considerations when evaluating these treatments. Different study designs, patient populations, and endpoints mean direct side effect comparisons require careful clinical interpretation. Both treatments showed that gradual dose escalation significantly reduced the incidence of severe gastrointestinal effects compared to rapid dose increases. This evidence supports the structured dosing protocols used by EverydayMeds prescribers when initiating either treatment.
How Wegovy Works: Understanding Side Effects Through Mechanism
Wegovy functions as a GLP-1 receptor agonist, mimicking natural incretin hormones that regulate appetite and gastric emptying. This mechanism directly explains why the most common side effects involve the gastrointestinal system, including nausea, reduced appetite, and changes in bowel movements. The medication slows gastric emptying, which contributes to increased satiety but can also cause feelings of fullness, bloating, and delayed digestion. GLP-1 receptors in the brain's appetite centres help reduce food cravings, but activation of these same receptors can trigger nausea responses in some individuals. The medication's effects on insulin sensitivity and glucose metabolism generally produce fewer side effects but can occasionally cause mild hypoglycaemia in susceptible patients. Understanding this mechanism helps patients anticipate and manage side effects more effectively during treatment.
Wegovy vs Mounjaro Side Effects: Ordering Process and Clinical Support
EverydayMeds streamlines access to both treatments through our comprehensive clinical assessment process. The 3-minute online questionnaire specifically evaluates your risk factors for common side effects, including gastrointestinal conditions and previous medication tolerances. Our prescribers review your assessment within 3 working days (or 24 hours with express service) to determine which treatment offers the optimal benefit-to-side-effect ratio for your circumstances. Once approved, next-day cold-chain delivery ensures your medication arrives in perfect condition, maintaining its efficacy and safety profile. Our clinical team remains available for ongoing support if you experience unexpected side effects or need dose adjustment guidance during your treatment journey.
Storage Requirements and Practical Side Effect Management
Proper storage plays a crucial role in maintaining medication effectiveness and minimising potential side effects from degraded products. Wegovy requires refrigeration at 2-8°C before first use, with a significant advantage of tolerating room temperature below 30°C for up to 6 weeks once removed from the fridge. This extended room temperature stability (compared to Mounjaro's 21-day limit) provides practical benefits for patients managing side effects through dose timing adjustments. The FlexTouch pen design enables precise dosing, which becomes particularly important when managing side effects through careful dose escalation. Patients experiencing significant side effects can work with prescribers to slow dose increases, extending time on lower doses as needed. The structured dose escalation from 0.25mg through to 2.4mg maintenance allows for personalised side effect management whilst maintaining treatment effectiveness.
Individual Tolerability: Why Wegovy vs Mounjaro Side Effects Vary
Personal response to Wegovy vs Mounjaro side effects depends heavily on individual factors including genetics, concurrent medications, underlying health conditions, and lifestyle factors. Some patients find GLP-1-only medications like Wegovy provide optimal tolerability, whilst others may benefit from tirzepatide's dual-receptor approach. Factors such as existing gastroparesis, previous bariatric surgery, or concurrent diabetes medications can significantly influence side effect experiences. Age, kidney function, and hepatic metabolism also play roles in determining individual tolerability profiles.
EverydayMeds prescribers consider these individual factors when recommending between treatments. Our clinical assessment captures relevant medical history that might predict side effect patterns or contraindicate specific treatments. The flexibility to access both medications through a single pharmacy ensures continuity of care if treatment switching becomes necessary due to tolerability issues. This comprehensive approach helps optimise treatment selection based on your unique side effect risk profile and clinical circumstances.
Making Your Choice: Expert Guidance on Wegovy vs Mounjaro Side Effects
Both Wegovy and Mounjaro are available from EverydayMeds, ensuring you can access whichever treatment your prescriber determines most suitable for your side effect tolerance and weight management goals. Our GPhC-registered pharmacy (#9012878) maintains comprehensive stocks of both medications, eliminating supply concerns that might force inappropriate treatment choices. The clinical assessment process evaluates your specific risk factors, previous medication experiences, and lifestyle considerations to recommend the optimal treatment. New customers can begin their assessment today using code FIRST40 applied at checkout, whilst returning customers benefit from code DOSE25. Visit https://everydaymeds.co.uk/collections/weight-loss to start your clinical assessment and receive expert guidance on managing potential side effects with either treatment option.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
